V
vitavitro
Innovative ART solutions with ISO-certified gamete and flushing buffer mediums for global regulatory compliance
About vitavitro
VitaVitro Biotech specializes in developing advanced Assisted Reproductive Technology (ART) solutions, including gamete buffer mediums and flushing buffer mediums. The company serves fertility clinics and medical institutions worldwide, operating primarily in the biotechnology and healthcare markets. VitaVitro's business model focuses on research, development, and commercialization of ART products, ensuring compliance with stringent global regulations such as ISO 13485:2016, and certifications in China, the USA, and the EU. Revenue is generated through the sale of these specialized products, which have received marketing approval from the National Medical Products Administration (NMPA) in China. The company is headquartered in Shenzhen, China, and actively participates in international conferences to showcase its innovations.
Source: Dealroom company dataAt a glance
- Headquarters
- China
- Sector
- Health
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
- CGChina Capital Investment Group
Med-Fine Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about vitavitro on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See vitavitro on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.